{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:04:44Z","timestamp":1785542684101,"version":"3.56.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.critrevonc.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,5,14]],"date-time":"2010-05-14T08:41:38Z","timestamp":1273826498000},"page":"92-111","source":"Crossref","is-referenced-by-count":102,"title":["Malignant pleural mesothelioma: The standard of care and challenges for future management"],"prefix":"10.1016","volume":"78","author":[{"given":"Jan P.","family":"van Meerbeeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle F.","family":"Surmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2010.04.004_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the ERS\/ESTS for management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Resp J"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.semtcvs.2009.06.007","article-title":"Current status of screening for malignant pleural mesothelioma","volume":"21","author":"Pass","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"9483","key":"10.1016\/j.critrevonc.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib4","series-title":"Prognostic factors in cancer","first-page":"165","author":"UICC","year":"2006"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00001622-200303000-00003","article-title":"The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma","volume":"15","author":"Eibel","year":"2003","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib7","series-title":"World Health Organization classification of tumours. Tumours of the lung, pleura, thymus and heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A Proposed New international TNM staging system for malignant pleural mesothelioma","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib9","series-title":"TNM atlas","author":"Wittekind","year":"2004"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2214\/ajr.172.4.10587144","article-title":"Staging of malignant pleural mesothelioma: comparison of CT and MR imaging","volume":"172","author":"Heelan","year":"1999","journal-title":"Am J Roentgenol"},{"issue":"13","key":"10.1016\/j.critrevonc.2010.04.004_bib11","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ejca.2009.04.028","article-title":"A Prognostic index for progression free survival in malignant mesothelioma with application to the design of phase II trial: an analysis of 10 combined EORTC trials","volume":"45","author":"Francart","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2010.04.004_bib12","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.lungcan.2005.03.032","article-title":"Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma","volume":"49","author":"Van Meerbeeck","year":"2005","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.critrevonc.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the EORTC experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.jtcvs.2007.02.014","article-title":"Ten traps for the unwary in surgical series: a case study in mesothelioma reports","volume":"133","author":"Treasure","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"10.1016\/j.critrevonc.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ijc.2910410409","article-title":"Survival patterns for malignant mesothelioma: the SEER experience","volume":"15, 41","author":"Spirtas","year":"1988","journal-title":"Int J Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2004.09.147","article-title":"Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module","volume":"22","author":"Nowak","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib19","series-title":"Video-assisted surgery or talc pleurodesis in treating patients with malignant mesothelioma","year":"2009"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002916.pub2","article-title":"Pleurodesis for malignant pleural effusions","author":"Shaw","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.127.3.909","article-title":"Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion","volume":"127","author":"Dresler","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1378\/chest.129.2.362","article-title":"Single-centre experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion","volume":"129","author":"Tremblay","year":"2006","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.critrevonc.2010.04.004_bib23","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M","article-title":"A randomised comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions","volume":"86","author":"Putnam","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thorax.57.11.939","article-title":"A systematic review of the use of opioids in the management of dyspnoea","volume":"57","author":"Jennings","year":"2002","journal-title":"Thorax"},{"issue":"14","key":"10.1016\/j.critrevonc.2010.04.004_bib25","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2007.15.5796","article-title":"Interventions for alleviating cancer-related dyspnea: a systematic review","volume":"26","author":"Ben-Aharon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.critrevonc.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/026921639601000405","article-title":"Non-pharmacological intervention for breathlessness in lung cancer","volume":"10","author":"Corner","year":"1996","journal-title":"Palliat Med"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib27","series-title":"World Health, Organization, Cancer pain, relief","year":"1986"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.54.3.238","article-title":"Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma","volume":"54","author":"Jackson","year":"1999","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00701-002-0945-2","article-title":"CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma","volume":"144","author":"Kanpolat","year":"2002","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1378\/chest.108.3.754","article-title":"Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomised trial of local radiotherapy","volume":"108","author":"Boutin","year":"1995","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6601957","article-title":"A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma","volume":"91","author":"Bydder","year":"2004","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2007.05.022","article-title":"A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma","volume":"84","author":"O\u2019Rourke","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2006.06.002","article-title":"The role of radiation therapy in malignant pleural mesothelioma: a systematic review","volume":"80","author":"Ung","year":"2006","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2010.04.004_bib34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1183\/09031936.00079407","article-title":"Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource","volume":"30","author":"Muirhead","year":"2007","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.critrevonc.2010.04.004_bib35","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1378\/chest.107.5.1454","article-title":"Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion","volume":"107","author":"Waller","year":"1995","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1010-7940(96)01008-1","article-title":"Pleurectomy\/decortication for palliation in malignant pleural mesothelioma: results of surgery","volume":"11","author":"Soysal","year":"1997","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejso.2004.08.014","article-title":"Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma","volume":"31","author":"Halstead","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejcts.2007.09.039","article-title":"The role of video assisted thoracoscopic pleurectomy\/decortication in the therapeutic management of malignant pleural mesothelioma","volume":"33","author":"Nakas","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib39","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1010-7940(01)00995-2","article-title":"Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control","volume":"20","author":"Martin-Ucar","year":"2001","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib40","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","article-title":"The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"9625","key":"10.1016\/j.critrevonc.2010.04.004_bib41","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib42","first-page":"245","article-title":"Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis","author":"Berghmans","year":"2003","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","article-title":"Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma","volume":"99","author":"S\u00f8rensen","year":"2008","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.04.004_bib44","first-page":"S347","article-title":"Tumour response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma","volume":"4","author":"Fennell","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"28","key":"10.1016\/j.critrevonc.2010.04.004_bib45","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomised phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"8, 99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2010.04.004_bib47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdj073","article-title":"A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial","volume":"17","author":"O\u2019Brien","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01243894-200601000-00007","article-title":"Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma","volume":"1","author":"Van den Bogaert","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"Suppl. 8","key":"10.1016\/j.critrevonc.2010.04.004_bib50","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80018-1","article-title":"Phase II trial of ZD0473 as second-line therapy in mesothelioma","volume":"38","author":"Giaccone","year":"2002","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib51","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B","article-title":"Chemotherapy of diffuse malignant mesothelioma, phase II trials of single-agent 5-fluorouracil and adriamycin","volume":"54","author":"Harvey","year":"1984","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2004.11.015","article-title":"Raltitrexed\u2013oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients","volume":"48","author":"Porta","year":"2005","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2010.04.004_bib53","first-page":"1431","article-title":"Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma","volume":"69","author":"Sorensen","year":"1985","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.22366","article-title":"Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma","volume":"109","author":"Fennell","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JTO.0b013e31802f3813","article-title":"Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment","volume":"2","author":"Sorensen","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2010.04.004_bib56","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2010.04.004_bib57","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2010.04.004_bib58","first-page":"15s","article-title":"Randomised multicentre phase IIIB study of ranpirnase+doxorubicin (DOX) versus DOX in patints with unresectable maligant lmesothelioma","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib59","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor, Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib60","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib61","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ijc.21271","article-title":"Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma","volume":"118","author":"Cortese","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib63","series-title":"A study of cetuximab combined with cisplatin or carboplatin\/pemetrexed as first line treatment in patients with malignant pleural mesothelioma","author":"Anonymous","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib64","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib65","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib67","first-page":"25","article-title":"Final analysis of a multi-centre, double-blind, placebo-controlled, randomised phase II trial of gemcitabine\/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)","author":"Karrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib68","series-title":"Bevacizumab (Avastin) and Erlotinib (Tarceva) in previously treated mesothelioma","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib69","series-title":"Carboplatin, bevacizumab and pemetrexed in the first-line treatment of patients with MPM","author":"Anonymous","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib70","first-page":"25","article-title":"Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307)","author":"Janne","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib71","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/annonc\/mdl017","article-title":"Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumours","volume":"17","author":"Richly","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib72","series-title":"Sorafenib in treating patients with malignant mesothelioma","year":"2009"},{"issue":"Suppl. 18","key":"10.1016\/j.critrevonc.2010.04.004_bib73","first-page":"24","article-title":"Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107)","author":"Jahan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib74","series-title":"Sunitinib in treating patients with advanced malignant pleural mesothelioma","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib75","series-title":"A study to find the best dose of SU011248 when given with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumours","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib76","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2010.04.004_bib77","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0169-5002(03)91684-9","article-title":"Thalidomide alone or in combination with cisplatin\/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomised phase II studies","volume":"41","author":"Pavlakis","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib78","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2005.07.010","article-title":"Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)","volume":"51","author":"Klabatsa","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib80","first-page":"22","article-title":"Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma","author":"Millward","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib81","first-page":"663","article-title":"A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM)","author":"Villano","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian group for mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib84","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib85","series-title":"Cisplatin, pemetrexed and imatinib mesylate in malignant mesothelioma","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib86","series-title":"A phase II study of the association of Glivec\u00ae Plus Gemzar\u00ae in patients with unresectable, refractory, malignant mesothelioma","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib87","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib88","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","article-title":"Histone deacetylase inhibitors as new cancer drugs","volume":"13","author":"Marks","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib89","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib90","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib91","series-title":"Suberoylanilide hydroxamic acid vorinostat, MK0683 versus placebo in advanced malignant pleural mesothelioma","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib92","series-title":"PXD101 as second-line therapy in treating patients with malignant mesothelioma of the chest that cannot be removed by surgery","author":"Anonymous","year":"2009"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.04.004_bib93","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib94","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","article-title":"Bortezomib inhibits nuclear factor-kappa B-dependent survival and has potent in vivo activity in mesothelioma","volume":"13","author":"Sartore-Bianchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib95","article-title":"Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma","author":"Gordon","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib96","series-title":"Bortezomib in treating patients with malignant pleural mesothelioma","author":"Anonymous","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib97","series-title":"Bortezomib and cisplatin as first-line therapy in treating patients with malignant mesothelioma","author":"Anonymous","year":"2009"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib98","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00001622-200303000-00005","article-title":"Indications and limitations of radiotherapy in malignant pleural mesothelioma","volume":"15","author":"Senan","year":"2003","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0360-3016(91)90054-8","article-title":"Deterioration in lung function following hemithorax irradiation for pleural mesothelioma","volume":"20","author":"Maasilta","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003880.pub4","article-title":"Radiotherapy for malignant pleural mesothelioma","author":"Chapman","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.04.004_bib101","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jtcvs.2004.02.021","article-title":"Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies","volume":"128","author":"Sugarbaker","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib102","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejcts.2006.01.015","article-title":"Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"29","author":"Opitz","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib103","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01243894-200602000-00014","article-title":"Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma","volume":"1","author":"Sugarbaker","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib104","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0003-4975(96)01228-3","article-title":"Patterns of failure after trimodality therapy for malignant pleural mesothelioma","volume":"63","author":"Baldini","year":"1997","journal-title":"Ann Thorac Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2010.04.004_bib105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib106","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0360-3016(02)04151-2","article-title":"Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma","volume":"55","author":"Ahamed","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.critrevonc.2010.04.004_bib107","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijrobp.2006.03.012","article-title":"Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma","volume":"65","author":"Allen","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.critrevonc.2010.04.004_bib108","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2007.04.076","article-title":"Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"84","author":"Rice","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib109","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy for malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01243894-200605000-00004","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial","volume":"1","author":"Flores","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"September (17)","key":"10.1016\/j.critrevonc.2010.04.004_bib111","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","article-title":"Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"22","author":"Weder","year":"2004","journal-title":"J Clin Oncol"},{"issue":"March (9)","key":"10.1016\/j.critrevonc.2010.04.004_bib112","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"De Perrot","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2010.04.004_bib113","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicentre trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.critrevonc.2010.04.004_bib114","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicentre phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1016\/j.critrevonc.2010.04.004_bib115","article-title":"Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031)","volume":"27","author":"Van Schil","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur Respir J"},{"issue":"Suppl. II","key":"10.1016\/j.critrevonc.2010.04.004_bib117","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thx.2007.087619","article-title":"BTS statement on malignant mesothelioma in the UK","volume":"62","author":"British Thoracic Society Standards of Care Committee","year":"2007","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib118","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.rmed.2006.10.018","article-title":"Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma","volume":"101","author":"Scherpereel","year":"2007","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib119","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","article-title":"The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J Thorac Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2010.04.004_bib120","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1093\/annonc\/mdn083","article-title":"Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Stahel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib121","unstructured":"NCCN Mesothelioma Panel Members. NCCN clinical practice guidelines in oncology. v.I. 2010, accessed at http:\/\/www.nccn.org."},{"key":"10.1016\/j.critrevonc.2010.04.004_bib122","unstructured":"Pinto C, Ardizzoni A,Giacomo Betta P, Facciolo F,Tassi G, et al. Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma. Am J Clin Oncol 2010 Apr 21. [Epub ahead of print]."},{"issue":"7010","key":"10.1016\/j.critrevonc.2010.04.004_bib123","first-page":"899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using update data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group","volume":"7311","year":"1995","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.critrevonc.2010.04.004_bib124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.JTO.0000263715.84567.5f","article-title":"Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma","volume":"2","author":"Krug","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"31","key":"10.1016\/j.critrevonc.2010.04.004_bib125","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2174\/1381612033453695","article-title":"Deaza analogs of folic acid as antitumour agents","volume":"9","author":"Kisliuk","year":"2003","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.critrevonc.2010.04.004_bib126","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11912-003-0098-3","article-title":"Novel antifolate drugs","volume":"5","author":"Purcell","year":"2003","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002800050422","article-title":"AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies","volume":"37","author":"Webber","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"30","key":"10.1016\/j.critrevonc.2010.04.004_bib129","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1200\/JCO.2007.12.5641","article-title":"Phase II study of vinflunine in malignant pleural mesothelioma","volume":"20, 25","author":"Talbot","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.04.004_bib130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF03256303","article-title":"Biomarkers for malignant pleural mesothelioma: current status","volume":"12","author":"Greillier","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib131","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesotheline expressing mesothelioma, ovarian and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib132","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","article-title":"Synergistic antitumour activity of taxol and immunotoxin SS1P in tumour-bearing mice","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib133","series-title":"A study of MORAb-009 in subjects with pancreatic cancer, mesothelioma or certain types of ovarian or lung cancer","author":"Anonymous","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib134","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms\u2019 tumour 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumour cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2010.04.004_bib135","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumour lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2010.04.004_bib136","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.critrevonc.2010.04.004_bib137","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/JTO.0b013e31818b174d","article-title":"Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study","volume":"3","author":"Hillerdal","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib138","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/bmj.328.7434.237","article-title":"Radical surgery for mesothelioma, the epidemic is still to peak and we need more research to manage it","volume":"328","author":"Treasure","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib139","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/JTO.0b013e3181ae26ae","article-title":"The mesothelioma and radical surgery randomised controlled trial: the MARS feasibility study","volume":"4","author":"Treasure","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/JTO.0b013e3181b7d470","article-title":"The MARS trial: resolution of the surgical controversies in mesothelioma?","volume":"4","author":"Rusch","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib141","series-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy. A randomised multicentre phase II trial (SAKK 1704)","author":"Swiss Group for Clinical Cancer Research","year":"2009"},{"issue":"9","key":"10.1016\/j.critrevonc.2010.04.004_bib142","first-page":"S774","article-title":"Feasibility of pleural Intensity-Modulated Radiation Therapy (IMRT) for malignant mesothelioma","volume":"4","author":"Rosenzweig","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib143","series-title":"Study using chemotherapy followed by intensity modulated radiation therapy to the pleura in patients with locally advanced but unresectable malignant pleural mesothelioma","year":"2009"},{"key":"10.1016\/j.critrevonc.2010.04.004_bib144","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"RadioGraphics"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281000082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281000082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:21:32Z","timestamp":1559107292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281000082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S104084281000082X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2010.04.004","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}